1 |
Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981;43:546-50
DOI
PUBMED
ScienceOn
|
2 |
Grunbaum Z, Freauff SJ, Krohn KA, Wilbur DS, Magee S, Rasey JS. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med 1987;28:68-75
PUBMED
|
3 |
Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-91
DOI
PUBMED
ScienceOn
|
4 |
Martin GV, Caldwell JH, Rasey JS, Grunbaum Z, Cerqueira M, Krohn KA. Enhanced binding of the hypoxic cell marker fluoromisonidazole in ischemic myocardium. J Nucl Med 1989;30:194-201
PUBMED
|
5 |
Caldwell JH, Revenaugh JR, Martin GV, Johnson PM, Rasey JS, Krohn KA. Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med 1995;36:1633-8
|
6 |
Strauss HW, Nunn A, Linder K. Nitroimidazoles for imaging hypoxic myocardium. J Nucl Cardiol 1995;2:437-45
DOI
ScienceOn
|
7 |
Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-60
|
8 |
Sinusas AJ. The potential for myocardial imaging with hypoxia markers. Semin Nucl Med 1999;29:330-8
DOI
PUBMED
ScienceOn
|
9 |
Ballinger JR, Kee JW, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996;37:1023-31
|
10 |
Stone CK, Mulnix T, Nickles RJ, Renstrom B, Nellis SH, Liedtke AJ, et al. Myocardial kinetics of a putative hypoxic tissue marker, -labeled nitroimidazole (BMS-181321), after regional ischemia and reperfusion. Circulation 1995;92:1246-53
DOI
PUBMED
ScienceOn
|
11 |
Shelton ME, Dence CS, Hwang DR, Welch MJ, Bergmann SR. Myocardial kinetics of fluorine-18 misonidazole: A marker of hypoxic myocardium. J Nucl Med 1989;30:351-8
PUBMED
|
12 |
Martin GV, Cerqueira MD, Caldwell JH, Rasey JS, Embree L, Krohn KA. Fluoromisonidazole. A metabolic marker of myocyte hypoxia. Circ Res 1990;67:240-4
DOI
PUBMED
ScienceOn
|
13 |
Shelton ME, Dence CS, Hwang DR, Herrero P, Welch MJ, Bergmann SR. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: A potential approach for identification of jeopardized myocardium. J Am Coll Cardiol 1990;16:477-85
DOI
PUBMED
|
14 |
Linder KE, Chan YW, Cyr JE, Nowotnik DP, Eckelman WC, Nunn AD. Synthesis, characterization, and in vitro evaluation of nitroimidazole--BATO complexes: New technetium compounds designed for imaging hypoxic tissue. Bioconjug Chem 1993;4: 326-33
DOI
ScienceOn
|
15 |
Johnson LL, Schofield L, Donahay T, Mastrofrancesco P. Myocardial uptake of a -nitroheterocycle in a swine model of occlusion and reperfusion. J Nucl Med 2000;41:1237-43
PUBMED
|
16 |
Johnson LL, Schofield L, Mastrofrancesco P, Donahay T, Nott L. Technetium-99m-nitroimadazole uptake in a swine model of demand ischemia. J Nucl Med 1998;39:1468-75
|
17 |
Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987;111:292-304
DOI
ScienceOn
|
18 |
Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-80
DOI
ScienceOn
|
19 |
Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KA. A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 1989;30:343-50
PUBMED
|
20 |
Ng CK, Sinusas AJ, Zaret BL, Soufer R. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia. Circulation 1995;92:1261-8
DOI
PUBMED
ScienceOn
|
21 |
Linder KE, Chan YW, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: Synthesis, characterization, and xanthine oxidase-catalyzed reduction. J Med Chem 1994;37:9-17
DOI
ScienceOn
|
22 |
Franko AJ. Misonidazole and other hypoxia markers: Metabolism and applications. Int J Radiat Oncol Biol Phys 1986;12:1195-202
DOI
PUBMED
ScienceOn
|
23 |
Jette DC, Wiebe LI, Chapman JD. Synthesis and in vivo studies of the radiosensitizer bromomisonidazole. Int J Nucl Med Biol 1983;10:205-10
DOI
ScienceOn
|
24 |
Shi CQ, Sinusas AJ, Dione DP, Singer MJ, Young LH, Heller EN, et al. Technetium-99m-nitroimidazole (BMS181321): A positive imaging agent for detecting myocardial ischemia. J Nucl Med 1995;36:1078-86
PUBMED
|
25 |
Okada RD, Johnson G, 3rd, Nguyen KN, Liu Z, Edwards B, Archer CM, et al. -HL91: 'hot spot' detection of ischemic myocardium in vivo by gamma camera imaging. Circulation 1998;97:2557-66
DOI
PUBMED
ScienceOn
|
26 |
Webster L. Drugs used in chemotherapy of protozoal infections. In: Gilman A, Rail T, Nies A, Taylor P, eds. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990:1002-4
|
27 |
Berne R, Levy M. Skeletal physiology. In: Berne R, Levy M, eds. Physiology. St. Louis: Mosby Yearbook, 1993:292-308
|
28 |
Jerabek PA, Patrick TB, Kilbourn MR, Dischino DD, Welch MJ. Synthesis and biodistribution of -labeled fluoronitroimidazoles: Potential in vivo markers of hypoxic tissue. Int J Rad Appl Instrum [A] 1986;37:599-605
DOI
ScienceOn
|